David R. Stover
Fate Therapeutics (United States)(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, Renal and related cancers, Cell Adhesion Molecules Research
Most-Cited Works
- → Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors(2000)1,280 cited
- PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.(2000)
- → Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models(2016)679 cited
- → Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma(2009)396 cited
- → Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors(1999)255 cited
- → Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma(2008)240 cited
- → Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α(1995)214 cited
- → New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis(2000)213 cited
- → New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development(1998)199 cited
- → Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma(2008)157 cited